Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Cash from Financing Activities (2018 - 2025)

Select Medical Holdings (SEM) has disclosed Cash from Financing Activities for 8 consecutive years, with -$31.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 83.08% to -$31.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$163.2 million, a 47.57% increase, with the full-year FY2025 number at -$163.2 million, up 47.57% from a year prior.
  • Cash from Financing Activities was -$31.0 million for Q4 2025 at Select Medical Holdings, up from -$135.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $133.0 million in Q1 2024 to a low of -$513.7 million in Q4 2021.
  • A 5-year average of -$74.2 million and a median of -$51.0 million in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 400.5% in 2023, then skyrocketed 3788.86% in 2024.
  • Select Medical Holdings' Cash from Financing Activities stood at -$513.7 million in 2021, then soared by 106.69% to $34.4 million in 2022, then crashed by 400.5% to -$103.3 million in 2023, then crashed by 77.18% to -$183.0 million in 2024, then soared by 83.08% to -$31.0 million in 2025.
  • Per Business Quant, the three most recent readings for SEM's Cash from Financing Activities are -$31.0 million (Q4 2025), -$135.0 million (Q3 2025), and -$46.5 million (Q2 2025).